{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:09:42Z","timestamp":1775675382437,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"novartis portugal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10792-021-02177-2","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T03:02:16Z","timestamp":1644634936000},"page":"1799-1809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Delphi study on the clinical management of age-related macular degeneration"],"prefix":"10.1007","volume":"42","author":[{"given":"Nuno","family":"Gomes","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-2786","authenticated-orcid":false,"given":"Angelina","family":"Meireles","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-7243","authenticated-orcid":false,"given":"\u00c2ngela","family":"Carneiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-0833","authenticated-orcid":false,"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0490-5889","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Campos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-0730","authenticated-orcid":false,"given":"Lilianne","family":"Duarte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-2418","authenticated-orcid":false,"given":"Rita","family":"Flores","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-2466","authenticated-orcid":false,"given":"Carlos","family":"Marques-Neves","sequence":"additional","affiliation":[]},{"name":"On behalf of the Portuguese RAMD consensus group","sequence":"additional","affiliation":[]},{"given":"Carolina","family":"Abreu","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Amaro","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Beato","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Amaro","sequence":"additional","affiliation":[]},{"given":"Diogo","family":"Cabral","sequence":"additional","affiliation":[]},{"given":"Maria","family":"da Luz Cachulo","sequence":"additional","affiliation":[]},{"given":"Joaquim","family":"Canelas","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9","family":"Coutinho","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia","family":"Farinha","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Figueira","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Filipe","family":"Fraga","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Furtado","sequence":"additional","affiliation":[]},{"given":"Filipe","family":"Isidro","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Lume","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Mendon\u00e7a","sequence":"additional","affiliation":[]},{"given":"Filipe","family":"Mira","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgio","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"S\u00edlvia","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Pita","family":"Negr\u00e3o","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Neves","sequence":"additional","affiliation":[]},{"given":"M\u00e1rio","family":"Ornelas","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Penas","sequence":"additional","affiliation":[]},{"given":"Sara Silva","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Sara Vaz","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Bernardete","family":"Pessoa","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Pires","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Roque","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Ru\u00e3o","sequence":"additional","affiliation":[]},{"given":"Gil Calv\u00e3o","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Filomena","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Teixeira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"2177_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mones J, Richard G, Bandello F, European Society of Retina S (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144\u20131167. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702","journal-title":"Br J Ophthalmol"},{"key":"2177_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"FG Holz","year":"2016","unstructured":"Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Larsen M, Weichselberger A, Wenzel A, Schmidt A, Escher D, Sararols L, Souied E (2016) Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled Study. Ophthalmology 123:1080\u20131089. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.030","journal-title":"Ophthalmology"},{"key":"2177_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/path.4266","volume":"232","author":"CM van Lookeren","year":"2014","unstructured":"van Lookeren CM, LeCouter J, Yaspan BL, Ye W (2014) Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 232:151\u2013164. https:\/\/doi.org\/10.1002\/path.4266","journal-title":"J Pathol"},{"key":"2177_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/bmj.326.7387.485","volume":"326","author":"A Chopdar","year":"2003","unstructured":"Chopdar A, Chakravarthy U, Verma D (2003) Age related macular degeneration. BMJ 326:485\u2013488. https:\/\/doi.org\/10.1136\/bmj.326.7387.485","journal-title":"BMJ"},{"key":"2177_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunovic H (2020) Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration. Ophthalmology 127:1211\u20131219. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.010","journal-title":"Ophthalmology"},{"key":"2177_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, Guymer RH (2016) The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2013a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol 16:31. https:\/\/doi.org\/10.1186\/s12886-016-0207-3","journal-title":"BMC Ophthalmol"},{"key":"2177_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000002470","volume":"40","author":"C Farinha","year":"2020","unstructured":"Farinha C, Santos T, Santos AR, Lopes M, Alves D, Silva R, Cunha-Vaz J (2020) Abnormal fluid under anti-vascular endothelial growth factor therapy. Retina 40:1\u201310","journal-title":"Retina"},{"key":"2177_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/bjophthalmol-2018-313447","volume":"104","author":"T Lin","year":"2020","unstructured":"Lin T, Dans KC, Muftuoglu IK, Meshi A, Amador-Patarroyo MJ, Cheng L, Freeman WR (2020) Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Br J Ophthalmol 104:58\u201363. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313447","journal-title":"Br J Ophthalmol"},{"key":"2177_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41433-020-0831-2","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Regillo CD (2020) Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD). Eye (Lond) 34:1310\u20131312. https:\/\/doi.org\/10.1038\/s41433-020-0831-2","journal-title":"Eye (Lond)"},{"key":"2177_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.8.6.3","volume":"8","author":"AJ Wightman","year":"2019","unstructured":"Wightman AJ, Abbott CJ, McGuinness MB, Caruso E, Guymer RH, Luu CD (2019) Presymptomatic retinal sensitivity changes in intermediate age-related macular degeneration associated with new retinal fluid. Trans Vis Sci Technol 8:3\u20133. https:\/\/doi.org\/10.1167\/tvst.8.6.3","journal-title":"Trans Vis Sci Technol"},{"key":"2177_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC (2015) Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 122:1212\u20131219. https:\/\/doi.org\/10.1016\/j.ophtha.2015.02.009","journal-title":"Ophthalmology"},{"key":"2177_CR12","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2017.67","volume":"31","author":"SR Rufai","year":"2017","unstructured":"Rufai SR, Almuhtaseb H, Paul RM, Stuart BL, Kendrick T, Lee H, Lotery AJ (2017) A systematic review to assess the \u201ctreat-and-extend\u201d dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye (Lond) 31:1337\u20131344. https:\/\/doi.org\/10.1038\/eye.2017.67","journal-title":"Eye (Lond)"},{"key":"2177_CR13","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1038\/s41598-020-64901-9","volume":"10","author":"J Siedlecki","year":"2020","unstructured":"Siedlecki J, Fischer C, Schworm B, Kreutzer TC, Luft N, Kortuem KU, Schumann RG, Wolf A, Priglinger SG (2020) Impact of sub-retinal fluid on the long-term incidence of macular atrophy in neovascular age-related macular degeneration under treat and extend anti-vascular endothelial growth factor inhibitors. Sci Rep 10:8036. https:\/\/doi.org\/10.1038\/s41598-020-64901-9","journal-title":"Sci Rep"},{"key":"2177_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1167\/tvst.9.9.48","volume":"9","author":"A Arrigo","year":"2020","unstructured":"Arrigo A, Aragona E, Di Nunzio C, Bandello F, Parodi MB (2020) Quantitative optical coherence tomography angiography parameters in type 1 macular neovascularization secondary to age-related macular degeneration. Transl Vis Sci Technol 9:48. https:\/\/doi.org\/10.1167\/tvst.9.9.48","journal-title":"Transl Vis Sci Technol"},{"key":"2177_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying G-S, Huang J, Martin DF, Jaffe GJ (2016) Macular morphology and visual acuity in the second year of the comparison of age-related\u00a0macular degeneration treatments trials. Ophthalmology 123:865\u2013875. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.002","journal-title":"Ophthalmology"},{"key":"2177_CR16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, De\u00e1k GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237\u20131245. https:\/\/doi.org\/10.1016\/j.ophtha.2013.12.029","journal-title":"Ophthalmology"},{"key":"2177_CR17","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.ophtha.2012.06.056","volume":"119","author":"SS Wickremasinghe","year":"2012","unstructured":"Wickremasinghe SS, Sandhu SS, Busija L, Lim J, Chauhan DS, Guymer RH (2012) Predictors of AMD treatment response. Ophthalmology 119:2413-2414.e2415. https:\/\/doi.org\/10.1016\/j.ophtha.2012.06.056","journal-title":"Ophthalmology"},{"key":"2177_CR18","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/iae.0000000000001736","volume":"38","author":"L Kodjikian","year":"2018","unstructured":"Kodjikian L, Decullier E, Souied EH, Roux A, Aulagner G, Huot L, Group ftGS (2018) Predictors of one-year visual outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Retina 38:1492\u20131499. https:\/\/doi.org\/10.1097\/iae.0000000000001736","journal-title":"Retina"},{"key":"2177_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM, Deak G-G, Kundi M, Simader C (2015) Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122:822\u2013832. https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.017","journal-title":"Ophthalmology"},{"key":"2177_CR20","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying G-S, Grunwald JE, Huang J (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:1860\u20131870. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.073","journal-title":"Ophthalmology"},{"key":"2177_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/aos.13565","volume":"96","author":"M Ashraf","year":"2018","unstructured":"Ashraf M, Souka A, Adelman RA (2018) Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol 96:120\u2013133. https:\/\/doi.org\/10.1111\/aos.13565","journal-title":"Acta Ophthalmol"},{"key":"2177_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.sjopt.2014.03.001","volume":"28","author":"KV Bhavsar","year":"2014","unstructured":"Bhavsar KV, Freund KB (2014) Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthalmol 28:129\u2013133. https:\/\/doi.org\/10.1016\/j.sjopt.2014.03.001","journal-title":"Saudi J Ophthalmol"},{"key":"2177_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.11.025","author":"RH Guymer","year":"2018","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ (2018) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with Ranibizumab using a treat-and-extend regimen: fluid study 24-month results. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025","journal-title":"Ophthalmology"},{"key":"2177_CR24","doi-asserted-by":"publisher","DOI":"10.48560\/rspo.14162","author":"CC Teixeira","year":"2018","unstructured":"Teixeira CC, Furtado MJ, Carneiro A, Silva R (2018) Degeneresc\u00eancia Macular da Idade (DMI) Guidelines de Tratamento 2018. Revista Sociedade Portuguesa de Oftalmologia. https:\/\/doi.org\/10.48560\/rspo.14162","journal-title":"Revista Sociedade Portuguesa de Oftalmologia"},{"key":"2177_CR25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/jama.2020.5576","volume":"324","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Peto T (2020) Current perspective on age-related macular degeneration. JAMA 324:794\u2013795. https:\/\/doi.org\/10.1001\/jama.2020.5576","journal-title":"JAMA"},{"key":"2177_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","volume":"124","author":"NS Abdelfattah","year":"2017","unstructured":"Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wykoff CC, Treat-and-Extend Age-Related Macular Degeneration Study G (2017) Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend Ranibizumab: findings from the trex-amd trial. Ophthalmology 124:215\u2013223. https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.002","journal-title":"Ophthalmology"},{"key":"2177_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ (2018) Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 125:878\u2013886. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.026","journal-title":"Ophthalmology"},{"key":"2177_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","volume":"124","author":"JE Grunwald","year":"2017","unstructured":"Grunwald JE, Pistilli M, Daniel E, Ying G-S, Pan W, Jaffe GJ, Toth CA, Hagstrom SA, Maguire MG, Martin DF (2017) Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology 124:97\u2013104. https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.012","journal-title":"Ophthalmology"},{"key":"2177_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12886-017-0544-x","volume":"17","author":"L Gonzalez-Buendia","year":"2017","unstructured":"Gonzalez-Buendia L, Delgado-Tirado S, Sanabria MR, Fernandez I, Coco RM (2017) Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab. BMC Ophthalmol 17:147. https:\/\/doi.org\/10.1186\/s12886-017-0544-x","journal-title":"BMC Ophthalmol"},{"key":"2177_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679\u2013680. https:\/\/doi.org\/10.1016\/j.ajo.2007.02.024","journal-title":"Am J Ophthalmol"},{"key":"2177_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","volume":"75","author":"J Ambati","year":"2012","unstructured":"Ambati J, Fowler Benjamin J (2012) Mechanisms of age-related macular degeneration. Neuron 75:26\u201339. https:\/\/doi.org\/10.1016\/j.neuron.2012.06.018","journal-title":"Neuron"},{"key":"2177_CR32","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L (2017) Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 124:1296\u20131304. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.057","journal-title":"Ophthalmology"},{"key":"2177_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43-58.e41. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024","journal-title":"Am J Ophthalmol"},{"key":"2177_CR34","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology 117:2134\u20132140. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.032","journal-title":"Ophthalmology"},{"key":"2177_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/412903","volume":"2015","author":"A Garcia-Layana","year":"2015","unstructured":"Garcia-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, Garcia-Arumi J, Gomez-Ulla F, Lopez-Galvez MI, Cabrera-Lopez F, Garcia-Campos JM, Mones J, Cervera E, Armada F, Gallego-Pinazo R (2015) Individualized therapy with ranibizumab in wet age-related macular degeneration. J Ophthalmol 2015:412903. https:\/\/doi.org\/10.1155\/2015\/412903","journal-title":"J Ophthalmol"},{"key":"2177_CR36","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"2177_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57-65.e55. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"2177_CR38","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"2177_CR39","doi-asserted-by":"publisher","first-page":"e820","DOI":"10.1111\/aos.14399","volume":"98","author":"MI Lopez Galvez","year":"2020","unstructured":"Lopez Galvez MI, Arias Barquet L, S. Figueroa M, Garcia-Layana A, Ruiz Moreno JM, In-Eye Study G (2020) Bimonthly, treat-and-extend and as-needed ranibizumab in naive neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study. Acta Ophthalmol 98:e820\u2013e829. https:\/\/doi.org\/10.1111\/aos.14399","journal-title":"Acta Ophthalmol"},{"key":"2177_CR40","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefe\u2019s Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 255:1259\u20131273. https:\/\/doi.org\/10.1007\/s00417-017-3647-4","journal-title":"Graefe's Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"key":"2177_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146\u2013152. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.041","journal-title":"Ophthalmology"},{"key":"2177_CR42","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","volume":"138","author":"PJ Kertes","year":"2020","unstructured":"Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T (2020) Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol 138:244\u2013250. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5540","journal-title":"JAMA Ophthalmol"},{"key":"2177_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189035","volume":"12","author":"T Hanemoto","year":"2017","unstructured":"Hanemoto T, Hikichi Y, Kikuchi N, Kozawa T (2017) The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLoS ONE 12:e0189035. https:\/\/doi.org\/10.1371\/journal.pone.0189035","journal-title":"PLoS ONE"},{"key":"2177_CR44","unstructured":"National Institute for Health and Care Excellence (2018) Age-related macular degeneration - NICE guideline, number 82."},{"key":"2177_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","volume":"39","author":"P Arendt","year":"2019","unstructured":"Arendt P, Yu S, Munk MR, Ebneter A, Wolf S, Zinkernagel MS (2019) Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration. Retina (Philadelphia, Pa) 39:27\u201333. https:\/\/doi.org\/10.1097\/IAE.0000000000001923","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2177_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","volume":"3","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Vaze A, Fraser-Bell S, Arnold J, Essex RW, Barthelmes D, Gillies MC (2019) Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. Ophthalmol Retina 3:623\u2013628. https:\/\/doi.org\/10.1016\/j.oret.2019.05.013","journal-title":"Ophthalmol Retina"},{"key":"2177_CR47","doi-asserted-by":"publisher","unstructured":"(2021) Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020. Ophthalmologe 118: 31\u201339 https:\/\/doi.org\/10.1007\/s00347-020-01188-1","DOI":"10.1007\/s00347-020-01188-1"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02177-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T13:20:46Z","timestamp":1654003246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02177-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02177-2","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gomes declares that he has no conflict of interest. Meireles has provided consultancy to Bayer. Carneiro has participated in advisory boards for Alcon, Allergan, Alimera Sciences, Bayer, Novartis and Roche. Silva has participated in advisory boards from Allergan, Alimera Sciences, Bayer, Novartis, Roche, THEA and NovoNordisk. Campos participated in advisory boards for Novartis. Duarte has received financial support from Alimera Sciences. Flores has provided consultancy to Allergan, Alimera Sciences, Bayer and Novartis. Marques-Neves participated in advisory boards from Novartis and received travel grants from Alimera Sciences. The authors have no proprietary or commercial interest in any materials discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}